ZLAB

Zai Lab Limited ADR (ZLAB) | Rumor.io

Zai Lab

ZLAB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,500

Bullish sentiment (50-day avg)74%

Price to earnings ratio-16

Market capitalization2.9B

Earnings per share-1.7

Dividend yield (TTM)—

Revenue (annual)460.2M

Net income (annual)-175.5M

Social

What share of all stock conversation is about ZLAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 6

ZLAB has experienced a significant price drop to $19.12.
The market is experiencing a "dumping season" with many investors selling their shares, referred to as "paper hands."
Investors who are holding onto their shares are being referred to as "diamond hands" and are often subject to memes and ridicule.

Generated by AI

Sentiment

Of the messages about ZLAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	20% -60.49	76.44% -7.12
Bearish	—	—	80% +60.49	23.56% +7.12

Jul 17

Zai Lab Limited's Efgartigimod has shown success in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a positive indication for the company.
Despite initial underperformance, investors are optimistic about Zai Lab's long-term potential, with some believing the company's market value will increase significantly in the future.
The company's VYVGART Hytrulo treatment has shown promise as a therapeutic alternative for CIDP patients in China, with positive results from the ADHERE study contributing to its recent stock price gains.

Generated by AI

Topics

Of the messages about ZLAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	84.16%
Technical Analysis	0%	0%	0%	3.76%
Analysts	0%	0%	0%	1.78%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	7.52%
Macro	0%	0%	0%	2.77%

Earnings· Mar 27

$ZLAB drops -1.82% after a conference call hosted by JPMorgan.
The conference call was a focus of market attention, with implications for the company's stock price.
Stock price movement suggests that investors were reacting to information shared during the call.

Announcements· Jan 31

Zai Lab Limited ($ZLAB) has announced participation in February investor conferences.
No additional market-relevant information was provided in the available posts.
A large block trade of $ZLAB shares occurred, with 238,000 shares traded at $41.65, totaling $9.91 million.

Generated by AI

Community

Of the messages about ZLAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.67%	75%	43.26%
Newcomers	0%	8.33%	25%	56.74%

Regulars· Aug 7

Zai Lab's Q2 earnings beat estimates for adjusted EPS, but missed on revenue, with sales increasing 9.43% YoY to $109.98M.
The company's adjusted EPS rose 54.88% YoY to $(0.37), but fell short of the estimated $(0.40).
Zai Lab's stock price declined 13.51% on August 7, 2025, to $33.49, despite the earnings beat, and some participants see a potential bounce opportunity at the 200 DMA.

Newcomers· Aug 7

$ZLAB reported 9% increase in Q2 revenues to $110.0M, beating expectations.
Zai Lab Limited reaffirmed full-year guidance of $560M to $590M.
Company's Q2 results were seen as a positive indicator of its growth prospects.

Generated by AI

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the

1d agoBenzinga

Zai Lab Ltd (1ZLB) Receives a Buy from UBS

Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.

11d agotheglobeandmail.com

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...

23d agoYahoo Finance

Guotai Haitong Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)

Tipranks Press Release.

1mo agoThe Globe and Mail

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

1mo agoYahoo Finance

Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB)

1mo agoSeeking Alpha

Also Discussed

Investors talking about ZLAB also mention

#	Name	Attention
1	HUTCHMED (China) Limited ADRHCM	0%0
2	BGNE - BeiGene, Ltd.	——
3	WisdomTree Inflation Plus FundWTIP	0%-0.02
4	I-Mab Sponsored ADRIMAB	0%0
5	Pacific NoS Global EM Equity Active ETFGEME	0%0
6	CSCI - COSCIENS Biopharma Inc.	——
7	LENSAR Inc.LNSR	0%0
8	argenx SE American Depositary ReceiptARGX	0%0
9	Kingsoft Cloud Holdings Ltd. ADRKC	0%0
10	Atour Lifestyle Holdings Limited Sponsored ADRATAT	0%new

Zai Lab Limited ADR

Healthcare
Biotechnology

Zai Lab Limited ADR is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious diseases with unmet medical needs. Zai Lab Limited ADR's current portfolio centers on oncology, immunology, infectious diseases, and neuroscience, with marketed products that help address conditions such as certain cancers, autoimmune disorders, and bacterial infections. The company works through a combination of in-house research, licensing, and global collaboration to bring medicines from development into commercial use. Its product lineup includes therapies such as Zejula, Optune, Qinlock, and Nuzyra, reflecting a business model that combines innovation with ongoing commercialization across specialty healthcare markets. Zai Lab Limited ADR plays a role in the biopharmaceutical sector by supplying treatments for complex conditions where therapeutic options remain limited, serving patients, healthcare providers, and partners across China and other international markets.

Website

Location

Building B

Pudong, 201203

China

Social

What share of all stock conversation is about ZLAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 6

ZLAB has experienced a significant price drop to $19.12.
The market is experiencing a "dumping season" with many investors selling their shares, referred to as "paper hands."
Investors who are holding onto their shares are being referred to as "diamond hands" and are often subject to memes and ridicule.

Generated by AI

Sentiment

Of the messages about ZLAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	20% -60.49	76.44% -7.12
Bearish	—	—	80% +60.49	23.56% +7.12

Jul 17

Zai Lab Limited's Efgartigimod has shown success in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a positive indication for the company.
Despite initial underperformance, investors are optimistic about Zai Lab's long-term potential, with some believing the company's market value will increase significantly in the future.
The company's VYVGART Hytrulo treatment has shown promise as a therapeutic alternative for CIDP patients in China, with positive results from the ADHERE study contributing to its recent stock price gains.

Generated by AI

Topics

Of the messages about ZLAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	84.16%
Technical Analysis	0%	0%	0%	3.76%
Analysts	0%	0%	0%	1.78%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	7.52%
Macro	0%	0%	0%	2.77%

Earnings· Mar 27

$ZLAB drops -1.82% after a conference call hosted by JPMorgan.
The conference call was a focus of market attention, with implications for the company's stock price.
Stock price movement suggests that investors were reacting to information shared during the call.

Announcements· Jan 31

Zai Lab Limited ($ZLAB) has announced participation in February investor conferences.
No additional market-relevant information was provided in the available posts.
A large block trade of $ZLAB shares occurred, with 238,000 shares traded at $41.65, totaling $9.91 million.

Generated by AI

Community

Of the messages about ZLAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.67%	75%	43.26%
Newcomers	0%	8.33%	25%	56.74%

Regulars· Aug 7

Zai Lab's Q2 earnings beat estimates for adjusted EPS, but missed on revenue, with sales increasing 9.43% YoY to $109.98M.
The company's adjusted EPS rose 54.88% YoY to $(0.37), but fell short of the estimated $(0.40).
Zai Lab's stock price declined 13.51% on August 7, 2025, to $33.49, despite the earnings beat, and some participants see a potential bounce opportunity at the 200 DMA.

Newcomers· Aug 7

$ZLAB reported 9% increase in Q2 revenues to $110.0M, beating expectations.
Zai Lab Limited reaffirmed full-year guidance of $560M to $590M.
Company's Q2 results were seen as a positive indicator of its growth prospects.

Generated by AI

Zai Lab

Social

Jul 6

Sentiment

Jul 17

Topics

Earnings· Mar 27

Announcements· Jan 31

Community

Regulars· Aug 7

Newcomers· Aug 7

News

The Insider Report: The Leaders Have Taken Off - DexCom (NASDAQ:DXCM), Zai Lab (NASDAQ:ZLAB)

Zai Lab Ltd (1ZLB) Receives a Buy from UBS

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Guotai Haitong Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB)

Also Discussed

Zai Lab Limited ADR

Company Information

Location

News

The Insider Report: The Leaders Have Taken Off - DexCom (NASDAQ:DXCM), Zai Lab (NASDAQ:ZLAB)

Zai Lab Ltd (1ZLB) Receives a Buy from UBS

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Guotai Haitong Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB)

Also Discussed

Social

Jul 6

Sentiment

Jul 17

Topics

Earnings· Mar 27

Announcements· Jan 31

Community

Regulars· Aug 7

Newcomers· Aug 7